Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 Vg/kg Cohort Following Giroctocogene Fitelparvovec Gene Therapy
$PFE $SGMO